Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
Calidi Biotherapeutics will present two posters at the ESMO Congress 2026 in Madrid on October 24, showcasing its RedTail virotherapy platform. New preclinical data on lead program CLD-401 will show high rates of complete tumor eradication in EMT6 breast cancer mouse models, plus retained antitumor activity in an MB49 bladder cancer model via both intravenous and intratumoral delivery. The company will also present preclinical data on its In Situ T-cell engager platform, including CLD-501 (TROP-2-targeted) and CLD-502 (EpCAM-targeted), demonstrating antigen-dependent, dose-responsive T-cell cytotoxicity.
Key figures
- Drug Name
- CLD-401
- Phase Of Trial
- Preclinical / IND-enabling studies
- Congress
- ESMO Congress 2026, Madrid, October 23-27, 2026
- Presentation date
- 2026-10-24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.